E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease (COPD) |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic disease of the lungs where the airways narrow over time, limiting the airflow to and from the lungs, and causing shortness of breath |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009033 |
E.1.2 | Term | Chronic obstructive pulmonary disease |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine whether adding low-dose theophylline to existing treatment (inhaled corticosteroid therapy) in patients who have chronic obstructive pulmonary disease will reduce the number of exacerbations (or flare-ups) of the condition. If the treatment is effective, we will also assess whether it is cost effective. |
|
E.2.2 | Secondary objectives of the trial |
The secondary research objectives are to compare: - hospital admissions with a primary diagnosis of exacerbation of COPD - emergency hospital admissions - lung functon - all-cause and respiratory mortality - drug reactions and serious adverse events - health related quality of life - disease specific health status - total inhaled corticosteroid dose/useage - heath care utilisiation - incremental cost-per-exacerbation avoided - lifetime cost effectiveness based on extrapolation modelling - modelled lifetime incemental cost per Quality Adjusted Life Year |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Aged ≥ 40 years. • A smoking history of at least 10 pack years. • An established predominant respiratory diagnosis of COPD (post bronchodilator FEV1/FVC<0.7). • Current use of ICS therapy (irrespective of LABA and/or LAMA use). • A history of at least two exacerbations requiring treatment with antibiotics and/or oral corticosteroid use in the previous year, based on patient report. • Clinically stable with no COPD exacerbation for at least 4 weeks. • Able to swallow study medication. • Able and willing to give informed consent to participate. • Able and willing to participate in the study procedures; undergo spirometric assessment, complete study questionnaire. |
|
E.4 | Principal exclusion criteria |
• Severe or unstable ischaemic heart disease. • A predominant respiratory disease other than COPD. • Any other significant disease/disorder which, in the investigator’s opinion, either puts the patient at risk because of study participation or may influence the results of the study or the patient's ability to participate in the study. • Previous allocation of a randomisation code in the study or current participation in another interventional clinical study. • Theophylline use currently. • Known or suspected hypersensitivity to theophylline. • Current use of drugs known to interact with theophylline and/or increase serum theophylline: antimicrobials: aciclovir, clarithromiycin, ciprofloxacin, erythromycin, fluconazole, ketoconazole, levofloxacin, norfloxacin; cardiovascular: diltiazem, mexiletine, pentoxifylline, verapamil; neurological: bupropion, disulfiram, fluvoxamine, lithium; hormonal: medroxyprogesterone, oestrogens; immunological: methotrexate, peginterferon alpha, tacrolimus; miscellaneous: cimetidine, deferasirox, febuxostat, roflumilast, thiabendazole. • For women, current pregnancy or breast-feeding, or planned pregnancy during the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary clinical outcome measure will be the total number of exacerbations of COPD necessitating changes in management (minimum management change - use of oral corticosteroids and/or antibiotics) during the one year treatment period, as reported by the participant. The primary economic outcome measure will be cost-per-QALY gained during the one year treatment period. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Approximately 12 months after entry into the trial. |
|
E.5.2 | Secondary end point(s) |
• Total number of COPD exacerbations requiring hospital admission. • Total number of emergency hospital admissions (all causes). • Post bronchodilator lung function (FEV1, FVC). • All-cause and respiratory mortality. • Serious adverse events, adverse reactions. • Total dose of inhaled corticosteroid. • Utilisation of primary or secondary health care for respiratory events • Disease specific health status using the COPD Assessment Test (CAT). • The Hull Airways Reflux Questionnaire (HARQ) will be used at some sites to collect data on respiratory and GI symptoms. • Generic health related quality of life using EuroQoL 5D (EQ-5D) Index. • Modelled lifetime incremental cost per Quality Adjusted Life Year. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Approximately 12 months after entry into the trial. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of clinical follow-up for each participant is defined as completion of the follow-up visit at 12 months. The end of clinical follow-up is when the last participant completes the follow-up visit at 12 months. The end of the trial is defined as the end of funding. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 31 |